Affimed N.V.
0HL9.L
London Stock Exchange0.00
USD
- -
- -
Affimed N.V.
0HL9.L
(London Stock Exchange)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company that develops innate cell engager (ICE) molecules for the treatment of cancer. The company focuses on redirecting innate immune cells, such as natural killer (NK) cells and macrophages, to target and destroy tumor cells through proprietary ROCK platform technologies; its lead ICE candidate, acimtamig (AFM13), targets CD30-positive hematologic malignancies, including Hodgkin lymphoma; additional pipeline candidates include AFM24, an EGFR-targeting ICE for solid tumors, and pre-clinical programs like AFM28 for AML. Affimed offers research collaboration services and licensing opportunities for its ICE platform to pharmaceutical partners. Founded in 2000 and headquartered in Heidelberg, Germany, the company operates primarily in Europe and the United States, with clinical trials conducted globally in North America, Europe, and Asia; it targets hematology-oncology markets, serving patients with relapsed or refractory cancers through partnerships with large pharma. In late 2024, Affimed entered a strategic alliance with Roche to advance acimtamig into a pivotal Phase 3 trial for relapsed/refractory Hodgkin lymphoma, triggering milestone payments; the company also reported positive topline data from the Phase 2 study of acimtamig in combination with Roche's Columvi in early 2025, supporting ongoing regulatory discussions. No major acquisitions, funding rounds, or name changes were reported in the last 1-2 years, though Affimed continues pipeline expansion with IND-enabling studies for next-generation ICE molecules.